| 1 |
35050442 | Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial. | 2022 May |
3 |
| 2 |
35585158 | Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability. | 2022 May 18 |
1 |
| 3 |
32052681 | Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage. | 2021 |
1 |
| 4 |
32944848 | Durable Disease Control with Regorafenib in a Patient with Metastatic KIT-Mutated Colorectal Cancer. | 2021 Jun |
1 |
| 5 |
33307872 | New insights into the clinical management of advanced gastrointestinal stromal tumors. | 2021 Mar |
1 |
| 6 |
33947686 | Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic Mastocytosis. | 2021 Jul |
1 |
| 7 |
31608707 | The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls. | 2020 Jan |
1 |
| 8 |
32024476 | Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors. | 2020 Feb 5 |
1 |
| 9 |
32207565 | Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium. | 2020 Jun |
1 |
| 10 |
30684595 | Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models. | 2019 Apr 10 |
1 |
| 11 |
30792533 | Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. | 2019 Mar |
1 |
| 12 |
31471313 | Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. | 2019 Dec 15 |
2 |
| 13 |
29334307 | Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model. | 2018 |
1 |
| 14 |
29359239 | The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma. | 2018 May |
1 |
| 15 |
29764854 | Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors. | 2018 Sep 1 |
2 |
| 16 |
30069758 | Regorafenib. | 2018 |
2 |
| 17 |
28478525 | Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors. | 2017 Jun |
2 |
| 18 |
26419617 | Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells. | 2016 May |
1 |
| 19 |
26651387 | The safety of regorafenib for the treatment of gastrointestinal stromal tumors. | 2016 Jan |
1 |
| 20 |
26865419 | Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma. | 2016 May |
1 |
| 21 |
27167336 | Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib. | 2016 Jul 5 |
1 |
| 22 |
27371698 | Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. | 2016 Sep |
1 |
| 23 |
26327919 | Management of regorafenib-related toxicities: a review. | 2015 Sep |
2 |
| 24 |
24384849 | Gastrointestinal stromal tumors: what do we know now? | 2014 Jan |
1 |
| 25 |
24405315 | Regorafenib for treatment of advanced gastrointestinal stromal tumors. | 2014 Mar |
2 |
| 26 |
24756792 | Regorafenib. | 2014 |
2 |
| 27 |
25239608 | Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. | 2014 Nov 15 |
2 |
| 28 |
23610528 | Critical appraisal of the use of regorafenib in the management of colorectal cancer. | 2013 |
1 |
| 29 |
22421192 | A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. | 2012 May 1 |
1 |
| 30 |
22577890 | Regorafenib for cancer. | 2012 Jun |
2 |
| 31 |
22614970 | Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. | 2012 Jul 1 |
1 |
| 32 |
21170960 | Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. | 2011 Jul 1 |
1 |